Dyslipidemia Management in 2020: An Update on Diagnosis and Therapeutic Perspectives

Author(s): Ioannis D. Karantas*, Mehmet E. Okur*, Neslihan Ü. Okur, Panoraia I. Siafaka

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders

Volume 21 , Issue 5 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Cardiovascular diseases are the leading cause of death in the modern world and dyslipidemia is one of the major risk factors. The current therapeutic strategies for cardiovascular diseases involve the management of risk factors, especially dyslipidemia and hypertension. Recently, the updated guidelines of dyslipidemia management were presented, and the newest data were included in terms of diagnosis, imaging, and treatment. In this targeted literature review, the researchers presented the most recent evidence on dyslipidemia management by including the current therapeutic goals for it. In addition, the novel diagnostic tools based on theranostics are shown. Finally, the future perspectives on treatment based on novel drug delivery systems and their potential to be used in clinical trials were also analyzed. It should be noted that dyslipidemia management can be achieved by the strict lifestyle change, i.e., by adopting a healthy life, and choosing the most suitable medication. This review can help medical professionals as well as specialists of other sciences to update their knowledge on dyslipidemia management, which can lead to better therapeutic outcomes and newer drug developments.

Keywords: Dyslipidemia, diagnosis, therapy, drug carriers, clinical trials, drug targets, cardiovascular risk.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 21
ISSUE: 5
Year: 2021
Published on: 06 May, 2021
Page: [815 - 834]
Pages: 20
DOI: 10.2174/1871530320666200810144004
Price: $65

Article Metrics

PDF: 171